Scott L. Burrows - 22 Dec 2023 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role: Chief Financial Officer
Signature: /s/ Heidy King-Jones, by power of attorney
Issuer symbol: SYRE
Transactions as of: 22 Dec 2023
Net transactions value: $0
Form type: 4
Filing time: 22 Dec 2023, 18:00:19 UTC
Previous filing: 05 Sep 2023
Next filing: 02 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRE	Common Stock	Award	$0	+134,953		$0.000000	134,953	22 Dec 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents 134,953 restricted stock units ("RSUs") granted under the Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, as Amended and Restated. Each RSU represents a contingent right to receive, upon vesting, one share of common stock, par value $0.0001 per share, of the Issuer. The RSUs vest as to one-fourth on each anniversary of September 1, 2023, subject to the Reporting Person's continued employment with the Issuer.

Content

Represents 134,953 restricted stock units ("RSUs") granted under the Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, as Amended and Restated. Each RSU represents a contingent right to receive, upon vesting, one share of common stock, par value $0.0001 per share, of the Issuer. The RSUs vest as to one-fourth on each anniversary of September 1, 2023, subject to the Reporting Person's continued employment with the Issuer.